Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Everest MedicinesHKSE:01952 -15.11%42 Gross Margin % is 70.01% as of Dec. 2025, which is 1% above its 10-year median of 69.25. GuruFocus rates HKSE:01952 with a GF Score™ of 42/100 and a GF Value™ of HK$297.41 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 732 Biotechnology companies, Everest Medicines ranks better than 59.02% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Everest Medicines had a gross margin of 70.01% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Everest Medicines Gross Margin % Related Terms
Everest Medicines Gross Margin % Historical Data
* Premium members only.
The historical data trend for Everest Medicines's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01952 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Everest Medicines's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Medicines Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Everest Medicines's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Everest Medicines's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Everest Medicines (HKSE:01952) has a Gross Margin % of 70.01% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Everest Medicines and its competitors. This is near median its historical median of 69.25. Over the past decade, Everest Medicines' Gross Margin % has ranged from 57.58 to 74.56. According to the industry distribution chart, Everest Medicines ranks #300 out of 732 companies in the Biotechnology industry, placing it in the top 41%.
Is Everest Medicines' Gross Margin % too high?
Everest Medicines' current Gross Margin % of 70.01% is near median its 10-year median of 69.25. Over the past 10 years, this metric has ranged from a low of 57.58 to a high of 74.56. The Biotechnology industry median Gross Margin % is 60.91. Everest Medicines' value of 70.01% is 14.9% above this industry median. Based on the distribution chart, Everest Medicines ranks #300 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Everest Medicines has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Everest Medicines ranks #300 out of 732 companies for Gross Margin %. This puts Everest Medicines in the upper half of its industry. The industry median Gross Margin % is 60.91. Everest Medicines' value of 70.01% is 14.9% above this benchmark. Historically, Everest Medicines' own Gross Margin % has ranged from 57.58 to 74.56 over the past decade. While the company's 10-year median is 69.25 vs. the industry median of 60.91, Everest Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Everest Medicines's current Gross Margin % of 70.01% is 14.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Everest Medicines and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Everest Medicines's current Gross Margin % is 70.01%, which is near median its own 10-year median of 69.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Possible Value Trap. The stock's GF Value™ is HK$297.41, compared to a current price of HK$24.72 — trading 91.7% below its estimated fair value. The current Gross Margin % is 70.01%, which is near median its 10-year median of 69.25 and 14.9% above the Biotechnology industry median of 60.91. Everest Medicines' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current Gross Margin % is 70.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Medicines (HKSE:01952) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued.
The current stock price of HK$24.72 is trading 91.7% below its estimated GF Value™ of HK$297.41.
GuruFocus considers Everest Medicines to be Possible Value Trap.
Key valuation signals for HKSE:01952:
Gross Margin %: 70.01% (near median its 10-year median of 69.25)
GF Value™: HK$297.41 vs. price of HK$24.72 (91.7% below fair value)
Industry Position: 14.9% above the Biotechnology median (#300 of 732)
No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
42GF Score
Get the complete analysis for HKSE:01952
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01952 has been successfully added to your 
